Virax Biolabs Group (Virax Biolabs Group) Interest Expense : $-0.02 Mil (TTM As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Virax Biolabs Group's interest expense for the six months ended in Sep. 2023 was $ -0.01 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.02 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Virax Biolabs Group's Operating Income for the six months ended in Sep. 2023 was $ -2.71 Mil. Virax Biolabs Group's Interest Expense for the six months ended in Sep. 2023 was $ -0.01 Mil. Virax Biolabs Group did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Virax Biolabs Group Interest Expense Historical Data

The historical data trend for Virax Biolabs Group's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group Interest Expense Chart

Virax Biolabs Group Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Interest Expense

-0.09

-0.03

-0.02

Virax Biolabs Group Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Interest Expense	Get a 7-Day Free Trial			-0.01	-	-0.01	-0.01	-0.01

Virax Biolabs Group Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.02 Mil.

Virax Biolabs Group (NAS:VRAX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Virax Biolabs Group's Interest Expense for the six months ended in Sep. 2023 was $-0.01 Mil. Its Operating Income for the six months ended in Sep. 2023 was $-2.71 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Sep. 2023 was $0.13 Mil.

Virax Biolabs Group's Interest Coverage for the quarter that ended in Sep. 2023 is calculated as

Virax Biolabs Group did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Virax Biolabs Group (Virax Biolabs Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 North Audley Street, London, GBR, W1K 6LX

Website

https://www.viraxbiolabs.com

Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.